Skip to main content
. Author manuscript; available in PMC: 2023 Feb 24.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1701–1711. doi: 10.1158/1078-0432.CCR-21-4239

Figure 2.

Figure 2.

Tumor infiltrating immune cells pre- and post- neoadjuvant therapy identified by RNA sequencing with analysis by Cofactor ImmunoPrism. (A) Percentage of immune infiltrating cells for all pooled sarcoma subtypes. Individual values, mean and standard deviations are shown. (B) Percentage of immune infiltrating cells by sarcoma subtype. UPS: Undifferentiated pleomorphic sarcoma (n=12); LMS: Leiomyosarcoma (n=2); MRCL: Myxoid/round cell liposarcoma (n=3); SS: Synovial Sarcoma (n=2); EW: Ewing sarcoma (n=2) and other (n=5). Comparisons for statistical differences in means were tested using two-tailed paired t-tests: * p-value < 0.05, *** p-value <0.001.